title: Hypoglycemia and blood glucose fluctuations in the application of a sensor-augmented insulin pump.
abstract: BACKGROUND
  The purpose of this study was to understand the effect of sensor-augmented insulin pump (SAP) use on hypoglycemia and blood glucose (BG) fluctuations.
  
  
  METHODS
  Sixty patients with type 2 diabetes mellitus were randomly assigned to three groups of treatment with SAP, continuous subcutaneous insulin infusion (CSII), or multiple daily injection (MDI) therapy for 6 days. Parameters of glycemic control that were determined included mean BG concentration (MBG), SD of BG (SDBG), mean amplitude of glycemic excursions (MAGE), absolute means of daily differences (MODD), 24-h area under the curve at 10 h (AUC10), 24-h area under the curve at 3.9 h (AUC3.9), and Low Blood Glucose Index (LBGI).
  
  
  RESULTS
  No significant differences were observed among the three groups in terms of MBG, SDBG, MAGE, or MODD at the beginning of treatment. The MBG, SDBG, MAGE, MODD, and total AUC10 of the SAP group improved over the 4 days of the intervention compared with the CSII and MDI groups; however, no significant differences were observed among the three groups in terms of total AUC3.9 and LBGI.
  
  
  CONCLUSIONS
  Compared with CSII and MDI therapy, SAP therapy was able to rapidly lower mean BG and reduce BG level fluctuations with no increased risks of hypoglycemia.
authors.affiliation: 1 Department of Endocrinology, General Hospital of Beijing Military Area , Beijing, China .
authors.forename: Pei
authors.initials: P
authors.lastname: Luo
authors.forename: Qianpeng
authors.initials: Q
authors.lastname: Cheng
authors.forename: Bin
authors.initials: B
authors.lastname: Chen
authors.forename: Yang
authors.initials: Y
authors.lastname: Li
authors.forename: Jinxiao
authors.initials: J
authors.lastname: Wu
authors.forename: Xingguang
authors.initials: X
authors.lastname: Zhang
authors.forename: Xiumin
authors.initials: X
authors.lastname: Jiao
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Xiaofeng
authors.initials: X
authors.lastname: Lv
mesh_terms: D000328:Adult; D019540:Area Under Curve; D015374:Biosensing Techniques; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015918:Infusion Pumps, Implantable; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; C517652:hemoglobin A1c protein, human